Signals, Powered By EquityPandit
Dr Reddy’s Laboratories has received an establishment inspection report (EIR) for Bachupally unit, Hyderabad, after the closure of its audit from the US Food and Drug Administration.
The audit for this formulation manufacturing plant 3 was conducted in April, by the USFDA and it issued a form 483 with 11 observations.
Further, this clearance from USFDA means that the company has resolved all the observations which were stated by the US health regulator.
